Background. Botulinum toxin type A (BoNTA) has been suggested as an effective anti-spastic drug. In this article, we summarized the data of randomized, placebo-controlled, double- blind trials and conducted a meta-analysis to assess if BoNTA is an adequate treatment for spasticity following stroke.
Objectives. To evaluate the relevant literature and assess the effectiveness and safety of BoNTA in (1) reducing spasticity based on mean change in the Modified Ashworth Scale (MAS) for upper and lower limb spasticity from baseline; (2) reducing spasticity based on the percent of patients having > or = 1point(s) change in the MAS; (3) improving the patient’s or caregivers’ Global Assessment Scale (GAS); and (4) total adverse events.
Method. We selected all randomized, placebo controlled, double-blind clinical trials or previous meta-analyses evaluating the efficacy and safety of BoNTA (Botox® or Dysport®) for the treatment of spasticity in both upper and lower limbs after stroke. Validity assessment of studies was performed, and Revman 4.2.7 from Cochrane Collaboration and SPSS (statistical package for the social sciences), v 9.0, were applied for analysis.
Results. Overall analysis showed clinical improvement between baseline and 4–6 weeks after application of BoNTA of the patient’s spasticity score using the MAS (weighted mean difference [WMD] = 0.87, 95% CI = 0.52–1.22). The odds ratio of the MAS spasticity score showing one or more points improvement at 4–6 weeks after giving BoNTA showed clinically significant improvement (OR = 4.5, 95% CI = 2.79–7.25). The odds ratio of having an improved GAS at 4–6 weeks after injecting BoNTA showed clinically significant improvement (Odds ratio = 5.85, 95% CI = 3.12–10.95). The odds ratio of having an adverse event during the entire study did not show any significant difference between placebo and BoNTA (odds ratio = 0.84, 95% CI = 0.55–1.28).
Reviewers’ conclusions. BoNTA improves muscle tone in upper and lower limb spasticity following stroke. A global assessment of improvement was noted by the patients or the caregivers following BoNTA injection. BoNTA is considered a safe therapeutic agent.
Bakheit, AMO, Pittock, S, Moore, AP, et al. 2001A randomized double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with strokeEur J Neurol8559565PubMedCrossRefGoogle Scholar
Bakheit, AMO, Thilman, AF, Ward, AB, et al. 2000A randomized double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type a with placebo in upper limb spasticity after strokeStroke3124022406PubMedGoogle Scholar
Bohannon, R, Smith, MB 1987Inter-rater reliability of the modified Ashworth scale of muscle spasticityPhys Ther67206207PubMedGoogle Scholar
Brashear, A, Gordon, MF, Elovic, E, et al. 2002Intra-muscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a strokeNew Engl J Med347395400PubMedCrossRefGoogle Scholar
Brashear, A, McAfee, A, Kuhn, E, Fyffe, J 2004Botulinum toxin type B in upper limb post-stroke spasticity: a double blind, placebo-controlled trialArch Phys Med Rehab85705709CrossRefGoogle Scholar
Burbaud, P, Wiart, L, Dubos, JL, et al. 1996A randomized, double-blind, placebo-controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patientsJ Neurol Neurosurg Psychiatry61265269PubMedCrossRefGoogle Scholar
Cardoso, E, Rodrigues, B, Lucena, R, et al. 2005Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysisArquives Neuropsiquiatry633033Google Scholar
Childers, MK, Brashear, A, Jozefczyk, P, et al. 2004Dose dependent response to intramuscular botulinum toxin type A for upper limb spasticity in patients after a strokeArch Phys Med Rehab8510631069CrossRefGoogle Scholar
Francis, HP, Wade, DT, Turner-Stokes, L, et al. 2004Does reducing spasticity translate into functional benefit? An exploratory meta-analysisJ Neurol Neurosurg Psychiatry7515471551PubMedCrossRefGoogle Scholar
Francisco, GE 2007Botulinum toxin for post-stroke spastic hypertonia: a review of its efficacy and application in clinical practiceAnn Acad Med Singapore362230PubMedGoogle Scholar
Fugoso, L, Rosales, RL, Delgado, M, Espiritu, G, Yusay, M, Salazar, G 2006Poststroke spasticity in the Philippines: definition, epidemiology and its pharmacologic therapy: a consensus statement of the Philippine Society of NeuroRehabilitationNeurorehab Neural Repair20198Google Scholar
Hesse, S, Reiter, F, Konrad, M, et al. 1998Botulinum toxin type A and short term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized double blind, placebo controlled trialClin Rehabil12381388PubMedCrossRefGoogle Scholar
Mezaki, T, Kaji, R, Hirota, N, et al. 1999Treatment of spasticity with muscle afferent blockNeurology5311561157PubMedGoogle Scholar
Pathak, MS, Nguyen, HT, Graham, HK, Moore, AP 2006Management of spasticity in adults: practical application of botulinum toxinEur J Neurol134250PubMedCrossRefGoogle Scholar
Pittock, SJ, Moore, AP, Hardiman, O, et al. 2003A double blind randomized placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport®) in the treatment of spastic equinovarus deformity after strokeCerebrovasc Dis15289300PubMedCrossRefGoogle Scholar
Rosales, RL, Bigalke, H, Dressler, D 2006Pharmacology of botulinum toxin: differences between type A preparationsEur J Neurol13210PubMedCrossRefGoogle Scholar
Simpson, DM, Alexander, DN, O’Brien, CF, et al. 1996Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trialNeurology4613061310PubMedGoogle Scholar
Smith, SJ, Ellis, E, White, S, et al. 2000A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injuryClin Rehabil14513PubMedCrossRefGoogle Scholar